-+ 0.00%
-+ 0.00%
-+ 0.00%
Lantheus’ Tauklaryfy PET imaging meets key endpoints in two Phase 3 Alzheimer’s studies
Share
Listen to the news
Lantheus’ Tauklaryfy PET imaging meets key endpoints in two Phase 3 Alzheimer’s studies
  • Lantheus presented positive results from two pivotal Phase 3 studies of TAUKLARIFY PET imaging at the CTAD meeting on Nov. 16, 2026.
  • Both studies met their primary diagnostic goals for detecting Alzheimer’s-related tau pathology, including in patients with early symptomatic disease.
  • Results showed consistent diagnostic performance across independent readers, supporting FDA use in adults with cognitive impairment undergoing evaluation for Alzheimer’s disease.
  • A pooled safety analysis found the imaging agent generally well tolerated.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantheus Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611160900PRIMZONEFULLFEED9877461) on November 16, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending